Increased CD154 expression in uninfected infants born to HIV-positive mothers exposed to antiretroviral prophylaxis (281 views)
Viral Immunol (ISSN: 0882-8245), 2006 Jun; 19(3): 363-372.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.133, 5-year impact factor: 1.892
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33750941974&partnerID=40&md5=d869a957875a5f604577f6b4ee32ef7a
Keywords: Antiretrovirus Agent, Cd40 Ligand, Spiramycin, Zidovudine, Antigen Expression, Cd4+ T Lymphocyte, Cd8+ T Lymphocyte, Clinical Article, Conference Paper, Controlled Study, Highly Active Antiretroviral Therapy, Human, Human Immunodeficiency Virus Infection, Immune Response, Immunostimulation, Infant, Peripheral Blood Mononuclear Cell, Postnatal Care, Prenatal Care, T Lymphocyte Activation, Toxoplasmosis, Treatment Outcome, Vertical Transmission, Virus Transmission, Cd4-Positive T-Lymphocytes, Cd8-Positive T-Lymphocytes, Child, Preschool, Disease Transmission, Female, Hiv Infections, Hiv Seropositivity, Newborn, Pregnancy, Pregnancy Complications, Viral Load,
Affiliations:
*** IBB - CNR ***
Department of Biochemistry and Medical Biotechnologies, Federico II Medical School, Naples University, Naples, Italy
Department of Pediatrics, Federico II Medical School, Naples University, Naples, Italy
Institute of Biostructure and Bioimaging-National Research Council (CNR), Naples, Italy
Institute of Child Health, University College London, London, United Kingdom
References:
Pozniak, A., Optimizing efficacy and tolerability in today's HAART (2003) AIDS Reader, pp. S4-S8. , revie
Katz, A., The evolving art of caring for pregnant women with HIV infection (2003) J Obst Gynecol Neonatal Nurs, 32, pp. 102-108
Moodley, D., Moodley, J., Coovadia, H., South African Intrapartum Nevapirine Trial (SAINT) investigators: A multicenter randomized controlled trial of nevapirine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1 (2003) J Infect Dis, 187, pp. 721-724
Bergamini, A., Cepparulo, M., Bolacchi, F., Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo (2002) Clin Exp Immunol, 130, pp. 293-299
Braun, M., Vierling, J.M., The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host (2003) Liver Transpl, 9, pp. S79-S89
Sipsas, N.V., Sfikakis, P.P., Kontos, A., Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4 + T-cell counts (2002) Clin Diagn Lab Immunol, 9, pp. 558-561
Clark, L.B., Foy, T.M., CD40 and its ligand (1996) Adv Immunol, 63, pp. 43-78
Grewal, I.S., Flavell, S.A., CD40 and CD154 in cell mediated immunity (1998) Annu Rev Immunol, 16, pp. 111-135
Lane, P., Traunecker, A., Hubele, S., Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes (1992) Eur J Immunol, 22, pp. 2573-2578
Larder, L.L., O'Fallon, S., Somoza, C., CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL (1995) J Immunol, 154, pp. 97-105
Bachmann, M.F., Kopf, M., Balancing protective immunity and immunopathology (2002) Curr Opin Immunol, 14, pp. 413-419
Kuwana, M., Kawakami, Y., Ikeda, Y., Suppression of autoreactive T-cell response to glycoprotein Iib-IIIia by blockade of CD40/CD154 interaction: Implications for treatment of immune thrombocytopenic purpura (2003) Blood, 101, pp. 621-623
Racke, M.K., Stuart, R.W., Targeting T cell costimulation in autoimmune disease (2002) Expert Opin Ther Targets, 6, pp. 275-289
Loken, M.R., Brosnan, J.M., Bach, B.A., Ault, K.A., Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry (1990) Cytometry, 11, pp. 453-459
Incorporating HIV prevention into the medical care of persons living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (2003) MMWR Recomm Rep, 52, pp. 1-24. , Centers for Disease Control and Prevention
and HIV Medicine Association of the Infectious Diseases Society of America
(2004) MMWR Recomm Rep, 53, p. 744. , Erratum
Coll, O., Fiore, S., Floridia, M., Pregnancy and HIV infection: A European consensus on management (2002) AIDS, 16 (SUPPL. 2), pp. S1-S18. , review
Landreau-Mascaro, A., Barret, B., Mayaux, M.J., Risk of early febrile seizure with perinatal exposure to nucleoside analogues (2002) Lancet, 359, pp. 583-584
Van Kooten, C., Bancherau, J., CD40-CD40 ligand: A multifunctional receptor-ligand pair (1996) Adv Immunol, 61, pp. 1-77
Glencross, D., Scott, L.E., Jani, I.V., Barnett, D., Janossy, G., CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration (2002) Cytometry, 50, pp. 69-77
Janossy, G., Jani, I.V., Bradley, N.J., Affordable CD4+ T-cell counting by flow cytometry: CD45 gating for volumetric analysis (2002) Clin Diagn Lab Immunol, 9, pp. 1085-1094
Kwekkeboom, J., De Boer, M., Tager, J.M., CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells (1993) Immunology, 79, pp. 439-444
Valentini, G., Romano, M.F., Naclerio, C., Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients (2000) J Autoimmun, 15, pp. 61-66
European Collaborative Study: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy (2005) Clin Infect Dis, 40, pp. 458-465
Bellòn Cano, J.M., Sànchez-Ramòn, S., Ciria, L., The effects on infants of potent antiretroviral therapy during pregnancy: A report from Spain (2004) Med Sci Monit, 10, pp. 179-184
Thorne, C., Newell, M.L., The safety of antiretroviral drugs in pregnancy (2005) Expert Opin Drug Saf, 4, pp. 323-335
Lipshultz, S.E., Easley, K.A., Orav, E.J., Absence of cardiac toxicity of zidovudine in infants (2000) N Engl J Med, 343, pp. 759-766
Zareba, K.M., Lavigne, J.E., Lipshultz, S.E., Cardiovascular effects of HAART in infants and children of HIV-infected mothers (2004) Cardiovasc Toxicol, 4, pp. 271-279
Le Chenadec, J., Mayaux, M.J., Guihenneuc-Jouyaux, C., Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants (2003) AIDS, 17, pp. 2053-2061
Bunders, M., Thorne, C., Newell, M.L., Maternal and infant factors and lymphocyte CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers (2005) AIDS, 19, pp. 1071-1079
Newell, M.L., Rogers, M., Pregnancy and HIV infection: A European consensus on management (2002) AIDS, 16 (SUPPL. 2)
Clerici, M., Sarasella, M., Colombo, F., T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV (2000) Blood, 96, pp. 3866-3871
Elliott, S.R., Roberton, D.M., Zola, H., Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children (2000) Hum Immunol, 61, pp. 378-388
Hamilton, B.J., Genin, A., Cron, R.Q., Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression (2003) Mol Cell Biol, 23, pp. 510-525
Kornbluth, R.S., The emerging role of CD40 ligand in HIV infection (2000) J Leukoc Biol, 68, pp. 373-382
Nepom, G.T., Erlich, H., MHC class-II molecules and autoimmunity (1991) Annu Rev Immunol, 9, pp. 493-525
Shevach, E.M., Regulatory T cells in autoimmunity (2000) Annu Rev Immunol, 18, pp. 423-449
Sipsas, N. V., Sfikakis, P. P., Kontos, A., Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4 + T-cell counts (2002) Clin Diagn Lab Immunol, 9, pp. 558-561
Clark, L. B., Foy, T. M., CD40 and its ligand (1996) Adv Immunol, 63, pp. 43-78
Grewal, I. S., Flavell, S. A., CD40 and CD154 in cell mediated immunity (1998) Annu Rev Immunol, 16, pp. 111-135
Larder, L. L., O'Fallon, S., Somoza, C., CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL (1995) J Immunol, 154, pp. 97-105
Bachmann, M. F., Kopf, M., Balancing protective immunity and immunopathology (2002) Curr Opin Immunol, 14, pp. 413-419
Racke, M. K., Stuart, R. W., Targeting T cell costimulation in autoimmune disease (2002) Expert Opin Ther Targets, 6, pp. 275-289
Loken, M. R., Brosnan, J. M., Bach, B. A., Ault, K. A., Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry (1990) Cytometry, 11, pp. 453-459
(2004) MMWR Recomm Rep, 53, p. 744. , Erratum
Bell n Cano, J. M., S nchez-Ram n, S., Ciria, L., The effects on infants of potent antiretroviral therapy during pregnancy: A report from Spain (2004) Med Sci Monit, 10, pp. 179-184
Lipshultz, S. E., Easley, K. A., Orav, E. J., Absence of cardiac toxicity of zidovudine in infants (2000) N Engl J Med, 343, pp. 759-766
Zareba, K. M., Lavigne, J. E., Lipshultz, S. E., Cardiovascular effects of HAART in infants and children of HIV-infected mothers (2004) Cardiovasc Toxicol, 4, pp. 271-279
Newell, M. L., Rogers, M., Pregnancy and HIV infection: A European consensus on management (2002) AIDS, 16 (SUPPL. 2)
Elliott, S. R., Roberton, D. M., Zola, H., Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children (2000) Hum Immunol, 61, pp. 378-388
Hamilton, B. J., Genin, A., Cron, R. Q., Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression (2003) Mol Cell Biol, 23, pp. 510-525
Kornbluth, R. S., The emerging role of CD40 ligand in HIV infection (2000) J Leukoc Biol, 68, pp. 373-382
Nepom, G. T., Erlich, H., MHC class-II molecules and autoimmunity (1991) Annu Rev Immunol, 9, pp. 493-525
Shevach, E. M., Regulatory T cells in autoimmunity (2000) Annu Rev Immunol, 18, pp. 423-449
Viral Immunol (ISSN: 0882-8245), 2006 Jun; 19(3): 363-372.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.133, 5-year impact factor: 1.892
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33750941974&partnerID=40&md5=d869a957875a5f604577f6b4ee32ef7a
Keywords: Antiretrovirus Agent, Cd40 Ligand, Spiramycin, Zidovudine, Antigen Expression, Cd4+ T Lymphocyte, Cd8+ T Lymphocyte, Clinical Article, Conference Paper, Controlled Study, Highly Active Antiretroviral Therapy, Human, Human Immunodeficiency Virus Infection, Immune Response, Immunostimulation, Infant, Peripheral Blood Mononuclear Cell, Postnatal Care, Prenatal Care, T Lymphocyte Activation, Toxoplasmosis, Treatment Outcome, Vertical Transmission, Virus Transmission, Cd4-Positive T-Lymphocytes, Cd8-Positive T-Lymphocytes, Child, Preschool, Disease Transmission, Female, Hiv Infections, Hiv Seropositivity, Newborn, Pregnancy, Pregnancy Complications, Viral Load,
Affiliations:
*** IBB - CNR ***
Department of Biochemistry and Medical Biotechnologies, Federico II Medical School, Naples University, Naples, Italy
Department of Pediatrics, Federico II Medical School, Naples University, Naples, Italy
Institute of Biostructure and Bioimaging-National Research Council (CNR), Naples, Italy
Institute of Child Health, University College London, London, United Kingdom
References:
Pozniak, A., Optimizing efficacy and tolerability in today's HAART (2003) AIDS Reader, pp. S4-S8. , revie
Katz, A., The evolving art of caring for pregnant women with HIV infection (2003) J Obst Gynecol Neonatal Nurs, 32, pp. 102-108
Moodley, D., Moodley, J., Coovadia, H., South African Intrapartum Nevapirine Trial (SAINT) investigators: A multicenter randomized controlled trial of nevapirine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1 (2003) J Infect Dis, 187, pp. 721-724
Bergamini, A., Cepparulo, M., Bolacchi, F., Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo (2002) Clin Exp Immunol, 130, pp. 293-299
Braun, M., Vierling, J.M., The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host (2003) Liver Transpl, 9, pp. S79-S89
Sipsas, N.V., Sfikakis, P.P., Kontos, A., Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4 + T-cell counts (2002) Clin Diagn Lab Immunol, 9, pp. 558-561
Clark, L.B., Foy, T.M., CD40 and its ligand (1996) Adv Immunol, 63, pp. 43-78
Grewal, I.S., Flavell, S.A., CD40 and CD154 in cell mediated immunity (1998) Annu Rev Immunol, 16, pp. 111-135
Lane, P., Traunecker, A., Hubele, S., Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes (1992) Eur J Immunol, 22, pp. 2573-2578
Larder, L.L., O'Fallon, S., Somoza, C., CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL (1995) J Immunol, 154, pp. 97-105
Bachmann, M.F., Kopf, M., Balancing protective immunity and immunopathology (2002) Curr Opin Immunol, 14, pp. 413-419
Kuwana, M., Kawakami, Y., Ikeda, Y., Suppression of autoreactive T-cell response to glycoprotein Iib-IIIia by blockade of CD40/CD154 interaction: Implications for treatment of immune thrombocytopenic purpura (2003) Blood, 101, pp. 621-623
Racke, M.K., Stuart, R.W., Targeting T cell costimulation in autoimmune disease (2002) Expert Opin Ther Targets, 6, pp. 275-289
Loken, M.R., Brosnan, J.M., Bach, B.A., Ault, K.A., Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry (1990) Cytometry, 11, pp. 453-459
Incorporating HIV prevention into the medical care of persons living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (2003) MMWR Recomm Rep, 52, pp. 1-24. , Centers for Disease Control and Prevention
and HIV Medicine Association of the Infectious Diseases Society of America
(2004) MMWR Recomm Rep, 53, p. 744. , Erratum
Coll, O., Fiore, S., Floridia, M., Pregnancy and HIV infection: A European consensus on management (2002) AIDS, 16 (SUPPL. 2), pp. S1-S18. , review
Landreau-Mascaro, A., Barret, B., Mayaux, M.J., Risk of early febrile seizure with perinatal exposure to nucleoside analogues (2002) Lancet, 359, pp. 583-584
Van Kooten, C., Bancherau, J., CD40-CD40 ligand: A multifunctional receptor-ligand pair (1996) Adv Immunol, 61, pp. 1-77
Glencross, D., Scott, L.E., Jani, I.V., Barnett, D., Janossy, G., CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration (2002) Cytometry, 50, pp. 69-77
Janossy, G., Jani, I.V., Bradley, N.J., Affordable CD4+ T-cell counting by flow cytometry: CD45 gating for volumetric analysis (2002) Clin Diagn Lab Immunol, 9, pp. 1085-1094
Kwekkeboom, J., De Boer, M., Tager, J.M., CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells (1993) Immunology, 79, pp. 439-444
Valentini, G., Romano, M.F., Naclerio, C., Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients (2000) J Autoimmun, 15, pp. 61-66
European Collaborative Study: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy (2005) Clin Infect Dis, 40, pp. 458-465
Bellòn Cano, J.M., Sànchez-Ramòn, S., Ciria, L., The effects on infants of potent antiretroviral therapy during pregnancy: A report from Spain (2004) Med Sci Monit, 10, pp. 179-184
Thorne, C., Newell, M.L., The safety of antiretroviral drugs in pregnancy (2005) Expert Opin Drug Saf, 4, pp. 323-335
Lipshultz, S.E., Easley, K.A., Orav, E.J., Absence of cardiac toxicity of zidovudine in infants (2000) N Engl J Med, 343, pp. 759-766
Zareba, K.M., Lavigne, J.E., Lipshultz, S.E., Cardiovascular effects of HAART in infants and children of HIV-infected mothers (2004) Cardiovasc Toxicol, 4, pp. 271-279
Le Chenadec, J., Mayaux, M.J., Guihenneuc-Jouyaux, C., Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants (2003) AIDS, 17, pp. 2053-2061
Bunders, M., Thorne, C., Newell, M.L., Maternal and infant factors and lymphocyte CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers (2005) AIDS, 19, pp. 1071-1079
Newell, M.L., Rogers, M., Pregnancy and HIV infection: A European consensus on management (2002) AIDS, 16 (SUPPL. 2)
Clerici, M., Sarasella, M., Colombo, F., T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV (2000) Blood, 96, pp. 3866-3871
Elliott, S.R., Roberton, D.M., Zola, H., Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children (2000) Hum Immunol, 61, pp. 378-388
Hamilton, B.J., Genin, A., Cron, R.Q., Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression (2003) Mol Cell Biol, 23, pp. 510-525
Kornbluth, R.S., The emerging role of CD40 ligand in HIV infection (2000) J Leukoc Biol, 68, pp. 373-382
Nepom, G.T., Erlich, H., MHC class-II molecules and autoimmunity (1991) Annu Rev Immunol, 9, pp. 493-525
Shevach, E.M., Regulatory T cells in autoimmunity (2000) Annu Rev Immunol, 18, pp. 423-449
Sipsas, N. V., Sfikakis, P. P., Kontos, A., Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4 + T-cell counts (2002) Clin Diagn Lab Immunol, 9, pp. 558-561
Clark, L. B., Foy, T. M., CD40 and its ligand (1996) Adv Immunol, 63, pp. 43-78
Grewal, I. S., Flavell, S. A., CD40 and CD154 in cell mediated immunity (1998) Annu Rev Immunol, 16, pp. 111-135
Larder, L. L., O'Fallon, S., Somoza, C., CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL (1995) J Immunol, 154, pp. 97-105
Bachmann, M. F., Kopf, M., Balancing protective immunity and immunopathology (2002) Curr Opin Immunol, 14, pp. 413-419
Racke, M. K., Stuart, R. W., Targeting T cell costimulation in autoimmune disease (2002) Expert Opin Ther Targets, 6, pp. 275-289
Loken, M. R., Brosnan, J. M., Bach, B. A., Ault, K. A., Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry (1990) Cytometry, 11, pp. 453-459
(2004) MMWR Recomm Rep, 53, p. 744. , Erratum
Bell n Cano, J. M., S nchez-Ram n, S., Ciria, L., The effects on infants of potent antiretroviral therapy during pregnancy: A report from Spain (2004) Med Sci Monit, 10, pp. 179-184
Lipshultz, S. E., Easley, K. A., Orav, E. J., Absence of cardiac toxicity of zidovudine in infants (2000) N Engl J Med, 343, pp. 759-766
Zareba, K. M., Lavigne, J. E., Lipshultz, S. E., Cardiovascular effects of HAART in infants and children of HIV-infected mothers (2004) Cardiovasc Toxicol, 4, pp. 271-279
Newell, M. L., Rogers, M., Pregnancy and HIV infection: A European consensus on management (2002) AIDS, 16 (SUPPL. 2)
Elliott, S. R., Roberton, D. M., Zola, H., Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children (2000) Hum Immunol, 61, pp. 378-388
Hamilton, B. J., Genin, A., Cron, R. Q., Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression (2003) Mol Cell Biol, 23, pp. 510-525
Kornbluth, R. S., The emerging role of CD40 ligand in HIV infection (2000) J Leukoc Biol, 68, pp. 373-382
Nepom, G. T., Erlich, H., MHC class-II molecules and autoimmunity (1991) Annu Rev Immunol, 9, pp. 493-525
Shevach, E. M., Regulatory T cells in autoimmunity (2000) Annu Rev Immunol, 18, pp. 423-449
Increased CD154 expression in uninfected infants born to HIV-positive mothers exposed to antiretroviral prophylaxis
Although prevention of mother-to-child HIV transmission by antiretroviral drugs has been shown to be effective, the short- and long-term effects of treatment are not well known. Several reports suggest that antiretroviral drugs act not only by inhibiting viral replication, but also by improving antiviral immunity. In particular, treatment with nucleoside analogs was found to increase CD40 ligand (CD40L; CD154) levels, an inducible molecule expressed on activated T lymphocytes. The present study investigated potential immunostimulatory effects of antiretroviral treatment (ART) in uninfected HIV-exposed infants, receiving either ante- or postnatal therapy to reduce the transmission rate. To this end, we analyzed CD40L expression in unstimulated lymphocytes from peripheral blood samples of uninfected infants vertically exposed to HIV and subjected to ART. The CD45 PanLeucogating strategy was applied in flow cytometry to analyze the lymphocytes of 41 cases and 64 age-matched infants, taken as control. We found increased CD154 expression on both CD4+ and CD8+ lymphocytes in ART-treated infants, compared with the controls. CD154 was apparently functional, because the expression of CD86 on monocytes was enhanced; moreover, inhibition of the CD40-CD40L interaction produced downmodulation of CD86. From these results, we conclude that CD4+ and CD8+ lymphocytes of HIV-exposed noninfected infants, who have been exposed to antiretroviral drugs in fetal and early life, display enhanced CD154 expression and costimulatory activity. © Mary Ann Liebert, Inc.
Although prevention of mother-to-child HIV transmission by antiretroviral drugs has been shown to be effective, the short- and long-term effects of treatment are not well known. Several reports suggest that antiretroviral drugs act not only by inhibiting viral replication, but also by improving antiviral immunity. In particular, treatment with nucleoside analogs was found to increase CD40 ligand (CD40L; CD154) levels, an inducible molecule expressed on activated T lymphocytes. The present study investigated potential immunostimulatory effects of antiretroviral treatment (ART) in uninfected HIV-exposed infants, receiving either ante- or postnatal therapy to reduce the transmission rate. To this end, we analyzed CD40L expression in unstimulated lymphocytes from peripheral blood samples of uninfected infants vertically exposed to HIV and subjected to ART. The CD45 PanLeucogating strategy was applied in flow cytometry to analyze the lymphocytes of 41 cases and 64 age-matched infants, taken as control. We found increased CD154 expression on both CD4+ and CD8+ lymphocytes in ART-treated infants, compared with the controls. CD154 was apparently functional, because the expression of CD86 on monocytes was enhanced; moreover, inhibition of the CD40-CD40L interaction produced downmodulation of CD86. From these results, we conclude that CD4+ and CD8+ lymphocytes of HIV-exposed noninfected infants, who have been exposed to antiretroviral drugs in fetal and early life, display enhanced CD154 expression and costimulatory activity. © Mary Ann Liebert, Inc.
Increased CD154 expression in uninfected infants born to HIV-positive mothers exposed to antiretroviral prophylaxis
No results. |
Increased CD154 expression in uninfected infants born to HIV-positive mothers exposed to antiretroviral prophylaxis
Other filter: ([btitle,keywords] "Antiretrovirus Agent ...
Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De RosaV, Colamatteo A, Micillo T, De Luca Picione C, Saccà F, De Rosa A, Moccia M, Brescia Morra V, Matarese G
* Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a (383 views)
Clin Immunol (ISSN: 1521-6616), 2017 Oct; 183: 249-253.
Impact Factor: 3.557
View Export to BibTeX Export to EndNote
Berisio R, Corti N, Pfister P, Yonath A, Böttger EC
* 23S rRNA 2058A→G alteration mediates ketolide resistance in combination with deletion in L22 (400 views)
Antimicrob Agents Ch (ISSN: 0066-4804, 1098-6596), 2006 Nov; 50(11): 3816-3823.
Impact Factor: 4.153
View Export to BibTeX Export to EndNote
* Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a (383 views)
Clin Immunol (ISSN: 1521-6616), 2017 Oct; 183: 249-253.
Impact Factor: 3.557
View Export to BibTeX Export to EndNote
Berisio R, Corti N, Pfister P, Yonath A, Böttger EC
* 23S rRNA 2058A→G alteration mediates ketolide resistance in combination with deletion in L22 (400 views)
Antimicrob Agents Ch (ISSN: 0066-4804, 1098-6596), 2006 Nov; 50(11): 3816-3823.
Impact Factor: 4.153
View Export to BibTeX Export to EndNote
2 Records (2 excluding Abstracts).
Total impact factor: 7.71 (7.71 excluding Abstracts).
Total 5 year impact factor: 8.528 (8.528 excluding Abstracts).
Total impact factor: 7.71 (7.71 excluding Abstracts).
Total 5 year impact factor: 8.528 (8.528 excluding Abstracts).
281 views. Last view on Saturday 14 January 2023, 19:33:21
ibb.cnr.it
